DSIP (Delta Sleep-Inducing Peptide)

Evidence Anchor

BioHarmony 6.1/10

DSIP sits at a low Neutral because it pairs a famous, overselling name with weak independent sleep evidence, a clean tolerability record, and one genuinely interesting but unproven withdrawal signal. The honest summary is that the peptide named after a sleep effect cannot reliably produce that effect in controlled humans, per Bes 1992 and Monti 1987, and almost all the positive sleep data trace to a single investigator. The thing actually worth a second look is its rapid relief of alcohol and opioid withdrawal in old, uncontrolled series, per Dick 1983. It is harmless to test, but it is not a dependable hypnotic, and there is no modern RCT. If you do decide to experiment, treat it the way I treat anything this thinly evidenced: verify your source, run it as a personal trial against your own response over a few weeks, and keep your expectations tied to the controlled data rather than the name on the vial. ✅ Best for: Curious experimenters who already understand the name oversells the sleep evidence and want to test a low-risk endogenous peptide on their own response. People intrigued by the unusual withdrawal-relief angle who treat it as a hypothesis, not a treatment. Anyone who values fast reversibility and a clean tolerability record and will judge DSIP by their own results over a few weeks rather than by the marketing. ❌ Avoid if: You expect a reliable sleep aid, because independent double-blind trials say the effect is weak, per Monti 1987. You want evidence-backed insomnia help, where oral melatonin or L-theanine are far better supported. You use opioids, sedatives, or alcohol, given the proposed and unstudied opioid-receptor interaction, per Dick 1983. You cannot verify your source, since grey-market product carries real sterility and purity risk. You are pregnant or breastfeeding, with no safety data.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.